Group 1 - The core viewpoint of the article highlights that Baoji Pharmaceutical-B (02659) has seen a significant stock price increase of over 6%, reaching a new high of 190 HKD, following its inclusion in the Hang Seng Composite Index [1] - The inclusion in the index will take effect after the market closes on March 6, 2026, and will expand the investment scope for the Hong Kong Stock Connect [1] - LiveReport's big data forecast suggests that Baoji Pharmaceutical is expected to leverage this opportunity to enter the Hong Kong Stock Connect, presenting new growth prospects [1] Group 2 - Baoji Pharmaceutical is known for its innovative products, including the first recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, and the globally first IgG degrading enzyme KJ103, which has "best-in-class" potential for treating antibody-mediated autoimmune diseases [1] - The company has established a clear commercialization model and timeline for its upcoming and current products, with KJ017 expected to receive NDA approval in the first quarter of 2026 [1] - Currently, KJ017 is not marketed as a standalone therapy in China, indicating potential for future growth once approved [1]
港股异动 | 宝济药业-B(02659)逆市涨超6%破顶 获纳入恒生综合指数 KJ017预计于26年首季度获NDA批准